Deca-Durabolin

(Nandrolone Decanoate)

ApprovedSmall molecule

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Deca-Durabolin is one of 155 small molecule programs targeting Malnutrition. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

Hip FractureActive, not recruiting

Weight LossActive, not recruiting

Total Hip ArthroplastyActive, not recruiting

SarcopeniaActive, not recruiting

MalnutritionPreclinical

Active, not recruiting

Hip FracturePhase 2

Active, not recruiting

Weight LossPhase 1

Active, not recruiting

Total Hip ArthroplastyApproved

Active, not recruiting

SarcopeniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Hip Fracture

#DrugCompanyPhaseTrials

Deca-Durabolin

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 2

Zometa

Pfizer

Phase 3

1 3

Lovenox

Sanofi

Phase 3

1 4

Crestor

AstraZeneca

Phase 3

1 5

Prolia

Amgen

Phase 3

1 6

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 7

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 8

Xarelto

WWim Janssens

Phase 3

2 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 10

PROCRIT

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Sarcopenia

NCT05978206

Post-ApprovalNot yet recruiting

Testosterone

NCT06462482

Post-ApprovalNot yet recruiting

Total Hip Arthroplasty

NCT06608914

Clinical

Trials by Indication[1]

Treatment1 trial

Nandrolone Decanoate in the Treatment of Telomeropathies

Completed·UUniversity of Sao Paulo·Phase 1/2·NCT02055456·20 enrolled

Dialysis Patients1 trial

Anabolic Steroids and Exercise in Hemodialysis Patients

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00250536·80 enrolled

Malnutrition1 trial

Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer

Completed·—·N/A·NCT03263520·60 enrolled

Sarcopenia1 trial

Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet

Recruiting·NNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 2·NCT05978206·168 enrolled

Testosterone1 trial

Peri-Operative Testosterone Administration in Primary Hip Arthroscopy

Not yet recruiting·AAmerican Hip Institute·Phase 4·NCT06462482·60 enrolled

4 more indications

Total Hip Arthroplasty1 trial

Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty

Not yet recruiting·AAmerican Hip Institute·Phase 4·NCT06608914·60 enrolled

Propranolol1 trial

Anabolic Steroid and Propranolol in Paediatric Burn

Unknown status·KKing Edward Medical University·N/A·NCT05805553·114 enrolled

Hip Fracture1 trial

Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.

Completed·MMorten Tange Kristensen PT, PhD·Phase 2·NCT03545347·29 enrolled

Weight loss1 trial

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000854·38 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 12, 1986

DECA-DURABOLIN

NDA NDA013132

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Nandrolone Decanoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nandrolone Decanoate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nandrolone Decanoate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013132). U.S. Food & Drug Administration.
[5]
SEC EDGAR — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Deca-Durabolin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Treatment1 trial

Dialysis Patients1 trial

Malnutrition1 trial

Sarcopenia1 trial

Testosterone1 trial

Total Hip Arthroplasty1 trial

Propranolol1 trial

Hip Fracture1 trial

Weight loss1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News